Chemotherapy for glioblastoma

Linz, Ute

doi:10.1002/cncr.23884

Cited by 6 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even with combined treatment including complete surgery, radiotherapy and chemotherapy, the survival time is estimated to be between 12 and 18 months following diagnosis ( 1 ). Chemotherapy is often used as a secondary treatment method for glioblastomas following the removal of the tumor by surgery, in order to prevent tumor recurrence ( 2 ). Since a curative outcome is unable to be achieved by surgery only, chemotherapy has become an essential adjuvant therapy for glioblastomas following surgery.…”

Section: Introductionmentioning

confidence: 99%

Effect of siRNA-Livin on drug resistance to chemotherapy in glioma U251 cells and CD133+ stem cells

Liu

Guo

Zhang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of the present study was to observe the effect of siRNA-Livin on the expression of multidrug resistance-associated protein (MRP) genes in a U251 cell line and U251 stem cells. CD133+ cancer stem cells were identified and isolated from the U251 glioblastoma cells, and morphological observations were used to detect the cell survival conditions. In addition, quantitative polymerase chain reaction was used to detect the mRNA expression levels of Livin, MRP1 and MRP3. Following transfection with the lentivirus containing the siRNA-Livin, the expression of Livin was significantly inhibited in the U251 cells and stem cells (P<0.01). Following temozolomide intervention, the proliferation of the U251 cells and U251 stem cells was restrained, with a lot of cell debris present and the structure of the cell spheres destroyed. The inhibitory effect was more significant following transfection with siRNA-Livin. Prior to siRNA-Livin transfection, the expression of MRP1 presented an increasing trend in the U251 cells and U251 stem cells with increasing drug concentrations and intervention times (P<0.05). Following siRNA-Livin transfection, the expression of MRP1 decreased in the U251 cells and U251 stem cells under the same drug concentration and intervention time (P<0.05), while the expression of MRP3 increased in the U251 stem cells under the same intervention concentration and time (P<0.05). Therefore, siRNA-Livin was shown to decrease the expression of MRP1 in U251 cells and U251 stem cells, increase the expression of MRP3 in U251 stem cells and decrease the proliferation of U251 cells and U251 stem cells. Thus, Livin may be associated with the high expression of MRP1, and siRNA-Livin may be used to lower the expression of MRP1 in order to reduce the drug resistance to chemotherapy in cases of glioblastoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of siRNA-Livin on drug resistance to chemotherapy in glioma U251 cells and CD133+ stem cells

Liu

Guo

Zhang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Recently, a randomized trial using ACNU plus teniposide (NOA-1) was directly compared with EORTC trial 26981, which applied TMZ [32,33] and a trend for better results after treatment with ACNU plus teniposide was observed. Our ATP assay results confirm this advantage of ATEN in comparison with TMZ, as is illustrated by the higher frequency of tumors inhibited by at least 90% at reference concentration TDC100 (Fig.…”

Section: Comparison Of Atp-tca and Ctr-testmentioning

confidence: 99%

Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas?

Linz¹,

Ulus²,

Neuloh³

et al. 2014

Anti-Cancer Drugs

Self Cite

View full text Add to dashboard Cite

Various in-vitro chemosensitivity and resistance assays (CSRAs) have been demonstrated to be helpful decision aids for non-neurological tumors. Here, we evaluated the performance characteristics of two CSRAs for glioblastoma (GB) cells. The chemoresponse of fresh GB cells from 30 patients was studied in vitro using the ATP tumor chemoresponse assay and the chemotherapy resistance assay (CTR-Test). Both assay platforms provided comparable results. Of seven different chemotherapeutic drugs and drug combinations tested in vitro, treosulfan plus cytarabine (TARA) was the most effective, followed by nimustine (ACNU) plus teniposide (VM26) and temozolomide (TMZ). Whereas ACNU/VM26 and TMZ have proven their clinical value for malignant gliomas in large randomized studies, TARA has not been successful in newly diagnosed gliomas. This seeming discrepancy between in vitro and clinical result might be explained by the pharmacological behavior of treosulfan. Our results show reasonable agreement between two cell-based CSRAs. They appear to confirm the clinical effectiveness of drugs used in GB treatment as long as pharmacological preconditions such as overcoming the blood-brain barrier are properly considered.

show abstract

Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5‐Year analysis of the EORTC‐NCIC trial (Lancet Oncol. 2009;10:459‐466)

Linz

2010

Cancer

Self Cite

View full text Add to dashboard Cite

Recently, un update of the important European Organization for Research and Treatment of Cancer study 26981 was published without correcting deficiencies that already were known and publicized in 2008. In the current commentary, the author specifies those issues to help prevent incorrect conclusions and discusses reasons why the journal that published the update dismissed a letter clarifying those shortcomings. Cancer 2010. © 2010 American Cancer Society.

show abstract

Chemotherapy for glioblastoma

Cited by 6 publications

References 17 publications

Effect of siRNA-Livin on drug resistance to chemotherapy in glioma U251 cells and CD133+ stem cells

Effect of siRNA-Livin on drug resistance to chemotherapy in glioma U251 cells and CD133+ stem cells

Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas?

Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5‐Year analysis of the EORTC‐NCIC trial (Lancet Oncol. 2009;10:459‐466)

Contact Info

Product

Resources

About